REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.

Abstract

INTRODUCTION:

A new treatment for coronavirus disease (COVID-19), REGN-COV2, a cocktail consisting of two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been approved for patients at a risk of developing more severe disease.

METHODS:

We retrospectively reviewed patients recently diagnosed with COVID-19 with risk factors for severe infection, who were treated with the REGN-COV2 antibody cocktail between July and September 2021. The REGN-COV2 antibody cocktail was administered to patients within 7 days of disease onset, with an oxygen saturation of >93%, and with at least one comorbidity. We investigated the percentage of patients with COVID-19-related hospitalization or death, the duration of symptoms after treatment, and the adverse effects of treatment.

RESULTS:

A total of 108 patients were reviewed. Of them, 64% were aged ≥50 years, 31% had obesity, 36% had hypertension, and 18% had diabetes. In addition, 49% had multiple risk factors for severe COVID-19. Overall, 12 patients (11%) needed COVID-19-related hospitalization. No adverse effects of treatment were observed.

CONCLUSIONS:

This study shows that treatment with the REGN-COV2 antibody cocktail is safe and beneficial in patients at a risk of developing severe COVID-19.

• Authors: Ayana Sakurai, Shoko Marshall, Tomoko Ogasawara, Toshie Ogasawara, Yoshikazu Aoka, Hiroshi Sakura, Yasuko Uchigata, Tetsuya Ogawa
• Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 28 Issue 7 Pg. 943-947 (Jul 2022) ISSN: 1437-7780 [Electronic] Netherlands
• PMID: 35414436 (Publication Type: Journal Article, Observational Study)
• Copyright: Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• Antibodies, Neutralizing
• Drug Combinations
• casirivimab and imdevimab drug combination

Topics

• Antibodies, Monoclonal, Humanized
• Antibodies, Neutralizing (therapeutic use)
• COVID-19
• Drug Combinations
• Humans
• Japan
• Retrospective Studies
• SARS-CoV-2